INTRODUCTION
============

Drug abuse often leads to a complex pharmaco-dependent state which is defined by the term addiction. Addiction is considered as a neuropsychiatric disease. It develops from an initial recreational drug use, evolves toward compulsive drug-seeking behavior and excessive drug-intake with the appearance of negative emotional states such as anxiety or irritability when the drug is not accessible, and uncontrolled intake reaching a stage where the drug interferes with daily activities, despite the emergence of adverse consequences ([@B76]; [@B35]; [@B138]; [@B70]). This pathological process develops in 15--30% of casual drug users and several factors may explain individual's vulnerability to addiction, including genetic, psychological and environmental factors ([@B161]; [@B5]; [@B126]; [@B145]). Addiction is a major threat to public health and represents a societal problem especially in developed countries and the economic cost it entails (investments in research, treatment and prevention) is considerable ([@B58]).

Among illicit drugs, opiate and cannabinoid derivatives are highly abused in Europe. Morphine-like opiates are powerful analgesics and currently represent the major therapeutic remedies for the treatment of severe pain. They are also abused for their recreational euphoric effects. In Europe, 1.3 million people are addicted to heroin, the primary drug for which treatment requests are sought. Cannabis is the most worldwide consumed drug of abuse, with THC being the most abundant active constituent found in the various preparations of the drug. More than 73 million European citizens have used cannabis in the last year and it is estimated that about 7% of cannabis users has become dependent on this drug. There is also a high prevalence of users who seek treatment for dependence on it (<http://www.emcdda.europa.eu/publications/edr/trends-developments/2014>). Interestingly, new derivatives of these abused drugs are invading the market, notably through internet. Fentanyl derivatives as new opioid drugs and synthetic cannabimimetics, also known as "spices," are becoming more and more popular ([@B38]). These abusive substances interact with two neuromodulator sytems, the opioid and the endocannabinoid systems.

THE OPIOID SYSTEM
-----------------

The opioid system consists of endogenous opioid peptides (enkephalins, endorphins, and dynorphins) from precursors (Penk, Pdyn, and Pomc) which activate three opioid receptors, namely mu, delta, and kappa ([@B65]). The three membrane receptors, cloned in the early nineties ([@B34]; [@B66]; [@B150], [@B151]; [@B107]) are GPCR with coupling to Gi/Go proteins, of which the 3D structure was recently resolved (see [@B41]). Opioid receptors and endogenous opioid peptides are largely expressed throughout the nervous system, noticeably within areas of the neurocircuitry of addiction associated with reward, motivation, or learning and stress ([@B95]; [@B73]; [@B71]; [@B33]). Besides its key role in many aspects of addition ([@B84]), the opioid system also plays a part in a diverse range of physiological functions including nociception, mood control, eating behavior, or cognitive processes ([@B19]; [@B131]; [@B158]; [@B9]; [@B116]).

THE ENDOCANNABINOID SYSTEM
--------------------------

The endocannabinoid system is a neuromodulatory system consisting of two well characterized transmembrane receptors coupled to G protein (Gi/Go), CB1, and CB2 cloned in the 1990's ([@B104]; [@B111]). The endogenous ligands are lipid neuromodulators, the main ones being AEA and 2-AG. Both are synthesized from phospholipid precursors and act locally as retrograde regulators of synaptic transmission throughout the central nervous system. These lipids are released by postsynaptic neurons and mainly activate presynaptic cannabinoid receptors to transiently or persistently suppress transmitter release from both excitatory and inhibitory synapses (recently reviewed in [@B118]). Multiple pathways are involved in AEA biosynthesis with several still not fully characterized enzymes. AEA can be generated from the membrane phospholipid precursor N-arachidonoyl phosphatidylethalonamine (NAPE) through a two-step process with first a calcium-dependent transacylase followed by a phospholipase D (NAPE-PLD) hydrolysis ([@B79]). Phospholipase C (PLC) and DAGL are involved in 2-AG synthesis ([@B3]). Their degradation is conducted by two specific enzymatic systems, the FAAH ([@B22]) and the MGL ([@B30]), for AEA and 2-AG, respectively ([@B3]). The endocannabinoid system plays a key role in energy balance, modulation of pain response, with processing of central and peripheral pain signals, learning and memory, reward and emotions. It has also been shown to be involved in neurogenesis and would play a neuroprotective role in some pathological conditions (for recent reviews see [@B50]; [@B156]; [@B91]; [@B185]; [@B122]; [@B129]). Distribution of the two receptors in the central and peripheral system is rather different ([@B127]). Indeed, CB1 is highly abundant in the central nervous system in areas involved in reward, regulation of appetite and nociception (see **Figure [1](#F1){ref-type="fig"}**) while CB2 was initially described as a peripheral receptor ([@B94], [@B91]; [@B89]). Recent studies have proposed a low but significant expression of this receptor in several brain structures including striatum, hippocampus, and thalamus ([@B181]; [@B56]; [@B119]) and more recently into ventral tegmental area neurons ([@B186]). Only few data are therefore available for the CB2 receptor in central function but growing evidence suggest a role in addictive processes, with an implication in cocaine, nicotine, or ethanol effects ([@B182]; [@B62]; [@B113]; [@B120]). To our knowledge, no data is available thus far concerning a potential role of CB2 in opioid mediated responses. Interestingly, other non-CB1 and non-CB2 receptors have been proposed to interact with endocannabinoids like the orphan GPCR GPR55 or a channel vanilloid TRPV1 recognizing capsaicin. These interactions could potentially explain some pharmacology of cannabis that cannot be accounted for by CB1 and CB2 activation, but further studies using KO approaches may help to provide a better understanding of this pharmacology ([@B27]).

![**Schematic representation of the distribution of mu opioid and CB1 cannabinoid receptors in the central nervous system.** CB1 receptor distribution over the whole central nervous system is indicated by circle shapes with low (white), moderate (gray) and high (dark gray) expression. Major localization of CB1 receptor (mRNA and protein) is in cortical areas, amygdala, striatum, and cerebellum. Moderate and low expression levels are observed in thalamic, hypothalamic, and brainstem regions. Interestingly, the mu opioid receptor is also expressed in these CB1 expressing brain areas but at various levels, indicated by diamonds for low (one), moderate (two), and high (three) expression levels (adapted from [@B88]; [@B33] and references therein). Amb, ambiguous nucleus; BLA, basolateral amygdala; CeA, central amygdala; CPu, caudate putamen; DB, diagonal band; DRN, dorsal raphe nucleus; GP, globus pallidus; Hyp, hypothalamus; LC, locus coeruleus; LHb, lateral habenular nucleus; mHb, medial habenular nucleus; NAc, nucleus accumbens; OB, olfactory bulb; PAG, periaqueductal gray; SNr, substantia nigra pars reticulate; Sol, nucleus of the solitary tract; STh, subthalamic nucleus (ventral thalamus); Th, dorsal thalamus; Tu, olfactory tubercle; VTA, ventral tegmental area.](fphar-06-00006-g001){#F1}

CROSS TALK BETWEEN THESE NEUROTRANSMITTER SYSTEMS
-------------------------------------------------

Many neurotransmitter systems are involved when addiction develops, and both opioid and endocannabinoid systems are major players in addictive disorders. In addition to their specific ligands, both systems have also been implicated in the action mechanism of several other addictive drugs, like ethanol, nicotine, or psychostimulants. Although the endocannabinoid system has been known to interact with other systems like hypocretin, dopaminergic, and adenosinergic systems ([@B39]; [@B40]; [@B165]), its interaction with the opioid system is now well established ([@B37]; [@B177]; [@B139]; [@B168]). These two systems share neuroanatomical, neurochemical, and pharmacological, characteristics, this phenomenon is yet less well documented for the CB2 receptor. **Figure [1](#F1){ref-type="fig"}** illustrates brain structures expressing CB1 receptors and depicts expression level of mu opioid receptors in these areas. The existence of a specific opioid--cannabinoid interaction in the modulation of neurochemical effects as well as behavioral responses associated with reward and relapse have been demonstrated by pharmacological and genetic approaches but experimental results remain controversial ([@B96]; [@B37]; [@B91]). Furthermore, molecular interactions between receptors have been shown with colocalization or heterodimerization data mainly for CB1 and delta or mu opioid receptors within spinal cord, striatum, or locus coeruleus. This phenomenon may also account for specific responses at the cellular level ([@B146]; [@B103]). However, the physiological effects of these molecular interactions have had yet to be revealed.

AIM OF THE REVIEW
-----------------

Pharmacological evidence for cross-talk with the synergetic effect of opioid and cannabinoid ligands in many functions related to addiction (mood, stress, learning process ...) have been revealed and here we will review the implications of both systems regarding reward aspects. As several reviews have recently reported about these interactions (see above), we will focus our interest only on genetic studies using KO mice. We will first present the available genetic tools for both systems. We will then provide an update of results on reinforced behaviors to highlight insights into the particular role of the opioid system in responses to cannabinoids and the endocannabinoid system in responses to prototypical opiates like morphine. We will summarize the behavioral responses of KO mice to these drugs and propose a role for the potential interaction of these two endogenous systems in addictive processes.

REWARD MEASURES IN MICE
=======================

Opioid and cannabinoid derivatives induce dependence. To study rewarding effects mediated by specific brain circuits in preclinical research, several behavioral models have been developed in rodents. The most reliable model to evaluate the reinforcing properties of a psychoactive compound in rodents is the self-administration (SA) paradigm which is based on a voluntary procedure to obtain the drug, coupled with the association of a signal ([@B123]). This operant system allows measuring both rewarding as well as motivational effects of an abused drug. Several aspect of addictive behaviors can be evaluated with this paradigm, with acquisition (fixed ratio) and motivation (progressive ratio) for the drug as well as extinction (response rate when drug-delivery has stopped) and reinstatement induced by cues, context or stress (relapse to drug-seeking) which will reflect aspects of excessive consumption ([@B144]). Intravenous SA has been extensively developed for opiates but more difficult to establish for cannabinoid compounds. Adaptations including drug priming, low doses, food restriction, animal restraint, or use of various cannabinoid agonists were often necessary ([@B90]; [@B124]; [@B122]). Nevertheless, iv SA of both THC and the synthetic cannabinoid WIN55,212-2 have been successfully described both in rats and mice, and extended to the study of KO mice ([@B100]; [@B36]; [@B106]; [@B43]). A very recent study demonstrated for the first time that 2-AG is self-administered by rats and stimulates DA transmission ([@B26]).

In addition, a well-accepted model to study the reinforcement properties of abused drugs is the CPP which is a non-operant paradigm. The reinforcing properties are associated with environmental stimuli (cues), such as the context in which the drug is administered. If the drug or a combination of drugs is aversive, animals avoid the drug-paired compartment (CPA) ([@B170]). These paradigms have been widely used to study opiates or cannabinoids effects in mutant mice. However, data reporting reinforcing properties for THC and other cannabinoids are rather controversial with a critical concern about experimental conditions, with dose or injection schedule as major parameters to reveal either positive CPP or negative CPA properties of cannabinoids ([@B122]).

On top of these two main paradigms (SA and CPP) other tasks have been developed like intracranial self-stimulation (ICSS) as a model to measure reward-facilitating effect of an abused substance although it is rather difficult to set up in mice and therefore little data is available ([@B122]). Furthermore, withdrawal signs appear after cessation of chronic drug exposure, either spontaneously or precipitated by an antagonist treatment, and these signs can be scored for providing an index of dependence ([@B92]). In order to make a meaningful comparison in the evaluation of the specific involvement of components of opioid or cannabinoid systems in reward process, it is crucial to compare, when possible, the different mutant lines with their WT littermates in the exact same procedure to avoid bias from technical or experimental variations. Interestingly, such direct comparison has been recently performed for the four components of the opioid system (mu, delta, Penk, and Pdyn) to demonstrate differential behavior in the acquisition and relapse of cocaine SA in the four mutant mice ([@B59]).

GENERATION OF DEFICIENT MICE IN REGARDS TO COMPONENTS OF THE OPIOID OR CANNABINOID SYSTEMS
==========================================================================================

For each component of the opioid and the cannabinoid systems, various lines of genetically modified mice have been generated. **Table [1](#T1){ref-type="table"}** presents a list for conventional KO mouse lines that have been described so far. The original papers describing the development of the constitutive deletion are presented with the targeted area of the suppressed gene.

###### 

Knockout mouse lines for the opioid and the cannabinoid systems.

  *Gene knockout*            Targeted exon                      Reference
  -------------------------- ---------------------------------- ----------------
  ***Opioid system***                                           
  *Oprm*                     Exon 2                             [@B105]
                             Exon 1                             [@B157]
                             Exon 1                             [@B166]
                             Exons 2 and 3                      [@B81]
                             Exon 1                             [@B148]
                             Exons 2 and 3                      [@B176]
                             Exon 11 (splice variant)           [@B121]
  *Oprd*                     Exon 2                             [@B187]
                             Exon 1                             [@B42]
                             Exon 2                             [@B176]
  *Oprk*                     Exon 1                             [@B153]
                             Exon 3                             [@B61]
                             Exon 3                             [@B4]
                             Exon 2                             [@B176]
                             Exon 3                             [@B175]
  *Oprm/oprd*                                                   [@B152]
  *Oprm/oprd/oprk*                                              [@B152]
                                                                [@B17]
  *Penk*                     Exon 3                             [@B69]
                             Exon 3                             [@B133]
  *Pdyn*                     Exon 3                             [@B149]
                             Exon 3                             [@B188]
                             Exon 3                             [@B80]
  *Pomc*                     Exon 3                             [@B141]
                             Exon 3                             [@B183]
  *Penk/Pdyn*                                                   [@B18]
  ***Cannabinoid system***                                      
  *Cnr1*                     Exon 2                             [@B189]
                             Exon 2                             [@B75]
                             Exon 2                             [@B99]
                             Exon 2                             [@B137]
  *Cnr2*                     Exon 2                             [@B63], [@B11]
                             Exon 2                             [@B181]
  *FAAH*                     Exon 1                             [@B21]
  *MGL*                      Exon 3                             [@B171]
                             Exons 3 and 4                      [@B164]
                             Intron 3--exon 4 (gene trapping)   [@B147]
                             Exons 1 and 2                      [@B14]
  NAPE-PLD                   Exon 4                             [@B77]
                             Exon 3                             [@B169]
  *DAGLalpha*                Exon 1                             [@B49]
                             Exons 3 and 4                      [@B163]
                             Intron 4-Exon 1(gene trapping)     [@B184]
  *DAGLbeta*                 Exon 1                             [@B49]
                             Exons 10 and 11                    [@B163]
                             Exon 1 (gene trapping)             [@B184]
  *cnr1/cnr2*                                                   [@B63]
  *FAAH/cnr1*                                                   [@B160]
  *FAAH/cnr2*                                                   [@B160]
  *FAAH/cnr1*                                                   [@B180]

This table summarizes the published report of KO mouse lines for the different partners of these two systems and combinatorial lines, with the original papers as reference. The area of the gene that has been targeted is indicated.

THE OPIOID SYSTEM
-----------------

For components of the opioid system, the mu receptor drew the most attention with the description of six distinct genetically modified lines targeting the coding regions of the *oprm* gene, with either exon 1, exon 2 or both exons 2 and 3 targeted for the deletion ([@B105]; [@B166]; [@B81]; [@B148]; [@B157]; [@B121]; [@B176]). Interestingly, the mu opioid receptor KO mice allowed to unambiguously demonstrate that the mu receptor was the molecular target for morphine, the prototype of opiate ligand widely used in clinics for its therapeutic effect in pain relief. Morphine had neither analgesic effects nor rewarding properties in these mutant mice (for reviews, see [@B19]; [@B51]). An additional mutant line was constructed which targeted exon 11, a splice variant for the mu receptor, located upstream of exon 1. In these deficient mice, a 25% decrease of receptor expression was observed ([@B121]), leading to difficult interpretation of the KO effect on opiate pharmacology ([@B51]). For deletion of the delta receptor, either exon 1 or 2 were targeted in the *oprd* gene ([@B187]; [@B42]; [@B176]). These mice were characterized for behavioral responses related to mood and analgesia, but the contribution of delta receptor in reward processes was less clear ([@B131]; [@B15]). Five distinct constructions have been reported targeting either exon 1, 2, or 3 of the *oprk* gene to obtain KO mice for the kappa opioid receptor ([@B153]; [@B61]; [@B4]; [@B176]; [@B175]). The two most recent mutants were strategically obtained in order to generate a parallel conditional KO mice (see below) using a Cre-lox approach, with targeted exons floxed with loxP sites. The mutation impaired pharmacological actions of the selective kappa-agonist U-50,488H, and revealed a tonic implication of kappa receptors in the perception of visceral pain. Morphine-CPP was unchanged, but both morphine withdrawal signs as well as emotional responses during opiate abstinence were reduced ([@B153]; [@B83]), suggesting an anti-reward role for kappa receptors.

Mice with deleted opioid peptide precursors were also generated. For proopiomelanocortin (*Pomc*), two lines were produced, one specifically deleting βendorphin ([@B141]) while the second was targeting the whole coding region, deleting both opioid and non-opioid active petides ([@B183]). KO mice for *Penk* gene were generated by two distinct laboratories, both leading to deletion of the 5^′^ part of exon 3 ([@B69]; [@B133]). For deleting dynorphin in mutant animals, exons 3 and 4 ([@B149]) or exon 3 with a part of exon 4 ([@B188]) of the *Pdyn* gene were targeted. Data from peptide KO mice in regards to opiate rewarding effect were more complex. The βendorphin KO mice showed increased ([@B154]) or unchanged ([@B115]) morphine-CPP depending on the dose and paradigm used and it was invariable both in mice lacking Penk ([@B154]) or Pdyn ([@B188]; [@B108]).

THE CANNABINOID SYSTEM
----------------------

Four independent KO lines have been generated for the CB1 receptor, encoded by a single large coding exon in the *cnr1* gene (exon 2). The first three lines were generated with the introduction of a PGK or neomycine resistance cassette in the coding region ([@B75]; [@B189]; [@B137]). For the fourth line, loxP sites were introduced flanking exon 2 and this floxed line was further crossed with a line constitutively expressing the Cre recombinase enzyme, therefore generating a full CB1 KO by deletion of the sequence between the two lox P sites ([@B99]). These mice were mostly unresponsive to cannabinoid ligands in mediating analgesia, reinforcement, hypothermia, hypolocomotion, and hypotension ([@B174]; [@B112]). Two mouse lines were described for the deletion of the *cnr2* gene coding for CB2 receptor, one by Zimmer's team ([@B63]; [@B11]) and the other one by the company Deltagen ([@B181]). Both were developed by deleting part of the coding region (in exon 2), leaving the start codon with a portion of the amino terminus sequence and aminoacids coding for some transmembrane domains of the receptor. In these constructions expression of the amino-terminal part of the CB2 receptor could potentially occur, but in both cases, it was shown that the receptor was non-functional in the mutant mice ([@B28]). Two mutant lines have been described for the NAPE-PLD enzyme involved in AEA synthesis, targeting exon 3 ([@B169]) or exon 4 ([@B77]). These KO mice have highlighted the complexity of AEA synthesis with both calcium-dependent and -independent mechanisms. Two isoforms of DAGLα and DAGLβ responsible for the synthesis of 2-AG have been described and KO lines have been generated for each of them with both homologous recombination and gene trapping approaches ([@B49]; [@B163]; [@B184]). The DAGLα KO animals showed a markedly reduced 2-AG brain content whereas levels were normal in brain regions of KO for the β isoform indicating a much greater contribution of DAGLα to 2-AG biosynthesis in the central nervous system. These mutant mice were particularly useful in the characterization of DAGL involvement in retrograde endocannabinoid signaling ([@B46]). The endocannabinoid system is characterized by a rapid catabolism of the endogenous ligands. Among the degrading enzymes of endocannabinoids, FAAH is the major enzyme responsible for the degradation of AEA and one KO line was generated targeting exon 1 of the *Faah* gene ([@B21]). These mutant mice exhibited more than 15-fold higher brain levels of AEA than WT animals and displayed reduced pain sensitivity. The major degrading enzyme of the endocannabinoid 2-AG is MGL and four KO lines were generated. Three KO lines targeting *mgll* gene exons 1 and 2 ([@B14]), exon 3, or exons 3 and 4 were recently generated with a Cre/lox approach ([@B164]; [@B171]). Another line was obtained by gene trapping technology (Texas Institute of Genomic Medicine) with a gene trap cassette inserted into the *mgll* intron 3, upstream of the catalytic exon 4 ([@B147]). Genetic deletion of MGL leads to alteration in endocannabinoid signaling with increased brain 2-AG levels by ∼10-fold. These animals were mainly characterized by behavioral consequences of the gene deletion for pain perception ([@B147]; [@B171]; [@B128]).

COMBINATORIAL MOUSE LINES
-------------------------

Interbreeding of mutant mouse lines allowed generating combinatorial mutant mice both within the opioid and the cannabinoid systems (see references in **Table [1](#T1){ref-type="table"}**). These combinatorial lines constituted useful tools to clarify the specific role of particular components of both systems in reward and analgesia, as well as to evaluate *in vivo* selectivity for specific ligands and receptor subtype identification ([@B67]; [@B112]). Data for reward responses obtained using multiple mutants for cannabinoid or opioid components are detailed below.

COMPENSATORY EFFECTS OF THE NULL MUTATION
-----------------------------------------

Globally, a normal development was described for the various mutant lines, with KO mice being fertile, caring for their offspring, and not showing any major behavioral abnormalities. A higher mortality rate was described for one of the CB1 KO line ([@B189]) but not reported for the two others. Interestingly, among the combinatorial mice, the triple mutant of the opioid receptors present a striking increase in body weight and size, but this obese-like phenotype needs further characterization (Befort and Gaveriaux-Ruff, personal communication). Compensatory mechanisms may have developed in some KO animals, but no systematic studies are available. Deletion of opioid receptors did not markedly modify the expression or activity of the other opioid receptors or the expression of opioid peptides as described by the initial characterizations of the distinct mutants lines (see references in **Table [1](#T1){ref-type="table"}** and [@B68]; [@B155]; [@B117]). A complete autoradiographic mapping of the delta KO mice indicated decreased binding levels of mu and kappa ligands in specific brain areas ([@B57]). Deletion of opioid peptides modified other partners of the opioid system, with a region-dependent increased of both mu and delta receptor expression levels observed in the Penk KO line ([@B10]; [@B18]) and for the three opioid receptors in the Pdyn and the double Pdyn/Penk mutant line with no additive effects ([@B18]). Interestingly, specific changes of CB1 receptor expression or activity were reported in mu and delta opioid receptor mutant lines ([@B8]). In the mu KO brain, there was no difference in CB1 expression but a decreased efficacy of the classical cannabinoid agonist WIN 55,212-2 was observed specifically in the CPu while both density of CB1 receptor and activation by WIN 55,212-2 increased in substantia nigra of delta KO animals.

Compensatory effects in KO animals concerning the cannabinoid system have been described both for receptor or catabolic enzyme KO mice. The invalidation of the CB1 receptor gene was associated with age-dependent adaptive changes of endocannabinoid metabolism, with increased FAAH and AEA membrane transporter activities in KO hippocampus and cortex, decreased AEA content in hippocampus but no change in 2-AG levels ([@B29]; [@B86], [@B87]). In the FAAH KO mice, CB1 receptor mRNA decreased in CPu, nucleus accumbens (core), hippocampus (CA1), hypothalamic nucleus (VMN), and amygdala. Its functional activity was also markedly reduced in CPu, the core of nucleus accumbens, and CA3 region of the hippocampus ([@B178]). Interestingly, reduction of CB1 receptor density and activity were also observed in MGL KO mouse brain, which may prevent the manifestation of the dramatically enhanced 2-AG behavioral effects in these mice ([@B14]; [@B147]). In DAGLα- and DAGLβ-KO, no difference was reported for CB1 mRNA ([@B49]) or protein ([@B163]) levels in comparison to WT mice. In these KO mice, CB1 brain functional signaling was unaltered ([@B1]). To our knowledge, no data is available for any compensatory effect on CB2 expression or activity in the distinct cannabinoid KOs. However, some reports indicate modifications of the opioid system in CB1 KO animals. An increase of both enkephalin and dynorphin mRNA expression was observed in the striatum ([@B159]; [@B54], [@B53]) as well as an increase in kappa and delta opioid receptor activities without changes in their binding ([@B172]). No compensatory changes of mRNA levels for the three opioid receptors were reported in dorsal root ganglia or spinal cord of the CB1 KO animals ([@B130]). In FAAH KO mice, Penk mRNA expression was decreased in both CPu and nucleus accumbens which paralleled a reduced mu opioid receptor functional activity ([@B178]). Noteworthy, these compensatory alterations of opioid or cannabinoid components in specific regions of the mutant lines could account for interactions of the two systems which may be relevant for neuroadaptative processes involved in drug dependence.

CONDITIONAL APPROACHES
----------------------

Knockout mice are very useful tools for understanding the contribution of each component of these systems in various conditions including pain, mood disorders or addiction ([@B174]; [@B51]; [@B85]; [@B112]; [@B15]). Recent approaches using gene manipulation in mice have been developed with the widely used Cre-loxP recombinase system to generate cKO ([@B44]; **Table [2](#T2){ref-type="table"}**). It consists of crossing mice whose target genes are floxed (flanked with two loxP sites) together with mice expressing the Cre-recombinase under a specific promoter. This allows a time-, organ- or site-specific deletion of a target gene. This strategy allowed uncoupling the central and peripheral functions of CB1 receptors ([@B2]) and more recently of mu or delta opioid receptors ([@B52]; [@B179]) using the promoter of the channel Nav1.8 only expressed in DRGs, revealing a key role for these receptors expressed in primary nociceptive neurons in inflammatory pain. To investigate molecular mechanisms at the level of neuronal circuitry, selective deletion of a particular gene can also be achieved in specific neuronal types. For example, deletion of the delta opioid receptors specifically in forebrain GABAergic neurons was obtained by crossing a delta opioid floxed mouse line ([@B52]) together with a dlx5-6-Cre mouse line, specifically expressing the Cre-recombinase in GABAergic forebrain neurons in order to investigate the role of these specific delta receptors in anxiety ([@B16]). This latter mouse line was previously crossed with the CB1 floxed mice to successfully obtain a GABA-CB1 conditional mutant ([@B110]). These mutants were also compared with several other cKO bearing a deletion of CB1 receptor in differing specific neuronal populations: forebrain glutamatergic neurons (CB1CamKIIa-Cre mice or CaMK-CB1KO), cortical glutamatergic neurons (CB1NEX-Cre mice or Glu-CB1KO), both glutamatergic and GABAergic neurons (Glu/GABA-CB1KO) or D1-dopaminergic neurons (CB1Drd1a-Cre mice) ([@B98]; [@B110], [@B109]; [@B6]) for studying the role of CB1 receptors as well as behavioral and autonomic effects of the agonist THC. For the opioid system, a recent study reported the generation of a conditional mutant for the kappa opioid receptor, selectively deleted in DA-expressing neurons. These kappa cKO mice showed reduced anxiety-like behavior as well as increased sensitivity to cocaine, consistent with a role for kappa receptors in negative regulation of DA function ([@B175]). For the cannabinoid system, cKO lines were also generated for the CB1 receptor to study its specific implication in neurons ([@B97]) or peripheral nerves ([@B132]), in serotoninergic ([@B32]) or paraventricular ([@B31]) and ventromedial ([@B7]) hypothalamic neurons. CB1 was also specifically deleted in astroglial cells to investigate its role in working memory and long-term hippocampal depression ([@B60]). CB1 was deleted in specific cell types like hepatocytes to study its role in ethanol-induced fatty liver ([@B64]), lymphocytes ([@B97]) or epidermal keratinocytes ([@B48]) to investigate its potential role in regulation of inflammatory responses. Another strategy to generate a cKO mouse is by using viral mediated construct carrying the Cre-recombinase injected directly in the structure of interest of a target gene-floxed mouse. For example, the mu opioid receptor was selectively deleted in the dorsal raphe, the main serotoninergic brain area, and this deletion abolished the development of social withdrawal in a model of heroin abstinence ([@B83]).

###### 

Conditional knockout mouse lines for the opioid and the cannabinoid systems.

  *Target Gene*              Targeted neurons or structures for selective deletion "loss of function"   Targeted neurons or structures for selective expression "rescue"   Reference
  -------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------ -----------
  ***Opioid system***                                                                                                                                                      
  *Oprm*                     Primary sensory neurons expressing Nav1.8 channel (Nav1.8-Cre)                                                                                [@B179]
                                                                                                        Subpopulation of striatal medium spiny neurons                     [@B24]
  *Oprd*                     Primary sensory neurons expressing Nav1.8 channel (Nav1.8-Cre)                                                                                [@B52]
                             Forebrain GABAergic neurons (Dlx5/6-Cre)                                                                                                      [@B16]
  *Oprk*                     Dopamine containing neurons (DAT-Cre)                                                                                                         [@B175]
  ***Cannabinoid system***                                                                                                                                                 
  *Cnr1*                     Principal forebrain neurons (CamKII-Cre)                                                                                                      [@B98]
                             Forebrain GABAergic neurons (Dlx5/6-Cre)                                                                                                      [@B110]
                             Cortical glutamatergic neurons (NEX-Cre)                                                                                                      [@B110]
                             Glutamatergic and GABAergic neurons (Glu/GABA)                                                                                                [@B6]
                             Primary sensory neurons expressing Nav1.8 channel (Nav1.8-Cre)                                                                                [@B2]
                             D1-dopaminergic neurons (Drd1a-Cre)                                                                                                           [@B109]
                             Serotoninergic neurons (TPH2-CreER^T2^)                                                                                                       [@B32]
                             Paraventricular hypothalamic neurons (Sim1-Cre)                                                                                               [@B31]
                             Ventromedial hypothalamic neurons (SF1-cre)                                                                                                   [@B7]
                             Neurons Nestin (Nes-Cre)                                                                                                                      [@B97]
                             Peripheral nerve (peripherin-Cre)                                                                                                             [@B132]
                             Astrocytes (GFAP- CreER^T2^)                                                                                                                  [@B60]
                             Hepatocytes (Alb-Cre)                                                                                                                         [@B64]
                             Lymphocytes (lck-Cre)                                                                                                                         [@B97]
                             Keratinocytes (K14-Cre)                                                                                                                       [@B48]
                                                                                                        Dorsal telencephalic glutamatergic neurons (Glu-CB1-RS)            [@B142]
  *FAAH*                                                                                                Nervous system (FAAH-NS)                                           [@B23]

This table summarizes the recent published reports of cKO mouse lines for the different partners of opioid and cannabinoid systems using "loss of function" or "rescue" strategies.

In opposition to the loss of function approach, recent studies used a rescue strategy where the target gene is re-expressed in a null mutant, in only a subset of cells (**Table [2](#T2){ref-type="table"}**). This helps to provide information concerning the sufficient role of the cell type expressing the target gene for a given function or establishing whether other cellular subtypes or circuits are necessary. When mu opioid receptor were re-expressed only in a subpopulation of striatal direct-pathway neurons, in a mu KO background, it restored opiate reward and opiate-induced striatal DA release, partially restored motivation to self-administer an opiate, but the rescued mice lacked opiate analgesia or withdrawal ([@B24]). In a similar genetic strategy, CB1 receptor expression was restored exclusively in dorsal telencephalic glutamatergic neurons and proved sufficient to control neuronal functions that are in large part hippocampus-dependent, while it was insufficient for proper amygdala functions ([@B142]). A conditional line where the expression of the FAAH enzyme has been restricted to the nervous system (FAAH-NS) was generated by crossing the FAAH KO line with a transgenic mouse, expressing FAAH under the neural specific enolase promoter ([@B23]). These mice exhibited a discrete subset of the biochemical and behavioral phenotypes observed in FAAH KO mice providing key insights into the distinct functions played by the central and peripheral lipids transmitter signaling systems **in vivo**.

In conclusion, despite potential limits such as developmental effects of the mutation or compensatory mechanisms to overcome consequences of the mutation, the use of mutants wherein a component of either opioid or cannabinoid system is selectively deleted from restricted neuronal populations provides essential tools for a comprehensive understanding of mechanisms underlying cannabinoid or opioid effects in reward circuitry. So far, these conditional lines for opioid and cannabinoid systems were mostly characterized for pain or emotional behavioral responses, and few data is yet to become available for reward aspects (**Table [2](#T2){ref-type="table"}**).

CANNABINOID REINFORCING EFFECTS IN OPIOID KNOCKOUT MICE
=======================================================

For evaluating the effect of cannabinoids in opioid mutant mice, THC-induced CPP was mostly used (**Table [3](#T3){ref-type="table"}**). Interestingly, the same protocol was used for all tested opioid KO mice with 1 mg/kg ip dose with a priming injection in the home cage. In these conditions, no differences in place preference induced by THC was observed in delta or kappa KO mice while THC-CPP was abolished in mu KO mutants ([@B55]) as well as in the double mu-delta KO mice ([@B13]). These data support the hypothesis that mu receptors mediate rewarding properties of THC. A similar protocol was used to induce aversion, but with a higher dose of THC (5 mg/kg ip) wherein mu KO mice showed a decreased CPA ([@B55]). THC-induced CPA was abolished in similar conditions in both Pdyn ([@B188]) and kappa KO mice ([@B55]). Self-administration of the synthetic cannabinoid agonist WIN55,212-2 was successfully established in freely moving mice with a low priming dose (0.1 mg/kg i.p.,) and with this protocol, Pdyn KO mice showed facilitated SA ([@B106]). Altogether, these data support the idea that the kappa/dynorphin system plays a key role in mediating cannabinoid dysphoric effects and therefore negatively modulates their rewarding effects ([@B106]). Contribution of delta receptors in reward appears complex ([@B15]; [@B59]) and it has not yet been established for cannabinoid reward, neither pharmacologically nor genetically. A potential role of this particular receptor in cannabinoid reward awaits further studies investigating either cannabinoid SA (motivation aspects) or delta cKO mutant responses (deletion of specific subpopulation of receptors).

###### 

Rewarding and dependence responses for cannabinoids and opioids measured in KO mouse lines for both systems.

  *Gene knockout*            Behavioral response                                                      Genotype effect         Reference
  -------------------------- ------------------------------------------------------------------------ ----------------------- -----------
  ***Opioid system***                                                                                                         
  *Oprm*                     CPP, THC (1 mg/kg, i.p.)                                                 Abolished               [@B55]
                             CPA THC (5 mg/kg, i.p.)                                                  Decreased               
                             WD, THC (20 mg/kg, i.p. 2x/d, 6d)                                        Unchanged               
                             WD, THC (10 mg/kg, s.c. 5d)                                              Unchanged               [@B78]
                             WD, THC (30 or 100 mg/kg, s.c. 5d)                                       Decreased               
  *Oprd*                     CPP, THC (1 mg/kg, i.p.)                                                 Unchanged               [@B55]
                             CPA THC (5 mg/kg, i.p.)                                                  Unchanged               
                             WD, THC (20 mg/kg, i.p. 2x/d, 6d)                                        Unchanged               
  *Oprm/Oprd*                CPP, THC (1 mg/kg, i.p.)                                                 Decreased               [@B13]
                             WD, THC (20 mg/kg, i.p. 2x/d, 6d)                                        Decreased               
  *Oprk*                     CPP, THC (1 mg/kg, i.p.)                                                 Unchanged               [@B55]
                             CPP, THC (1 mg/kg, i.p.)w/o priming                                      Present, absent in WT   
                             CPA, THC (5 mg/kg, i.p.)                                                 Abolished               
                             WD, THC (20 mg/kg, i.p. 2x/d, 6d)                                        Unchanged               
  *Penk*                     WD, THC (20 mg/kg, i.p. 2x/d, 6d)                                        Decreased               [@B173]
  *Pdyn*                     CPA, THC (5 mg/kg, i.p.)                                                 Abolished               [@B55]
                             SA, WIN 55,212(6.25 mg/kg/inf, i.v.)                                     Increased               [@B106]
                             SA, WIN 55,212(12.5 mg/kg/inf, i.v.)                                     Abolished               
                             WD, THC (20 mg/kg, i.p. 2x/d, 6d)                                        Decreased               [@B188]
  ***Cannabinoid system***                                                                                                    
  *Cnr1*                     CPP, morphine (5 mg/kg, s.c.)                                            Abolished               [@B101]
                             CPA, morphine + naloxone (20--100 mg/kg i.p. over 6d + 0.1 mg/kg s.c.)   Unchanged               
                             CPP, morphine (4--8 mg/kg, i.p.)                                         Unchanged               [@B136]
                             CPA, morphine + naloxone (8 mg/kg + 5 mg/kg, i.p.)                       Unchanged               
                             SA, morphine (2 ug/kg.inf, i.v.)                                         Abolished               [@B20]
                             SA, morphine (1, 2, 4 ug/kg/inf, i.v.)                                   Decreased               [@B75]
                             WD, morphine (20 mg/kg to 100 mg/kg, 5d)                                 Decreased               
                             WD, morphine (75 mg/kg pellet, 5d)                                       Decreased               [@B78]
                             CPA, U50,488H (1 mg/kg, s.c.)                                            Abolished               [@B75]

This table summarizes published reports of behavioral responses in reward and precipitated withdrawal for cannabinoids in opioid KO lines and opioids in cannabinoid KO mutants (CPA, conditioned place aversion; CPP, conditioned place preference; d, day; inf, infusion; i.p., intraperitoneal; s.c., subcutaneous; WD, withdrawal; w/o, without).

Another aspect that was explored in opioid KO mice is cannabinoid dependence. Upon chronic THC treatment, antagonist-induced withdrawal signs measured in WT animals were unchanged for Pdyn KO ([@B188]) or single mutant mice for mu, delta or kappa opioid receptors ([@B55]). Signs were attenuated in KO animals for Penk ([@B173]), for the double mu-delta receptor mutant ([@B13]) as well as for mu receptor KO, at a high dose ([@B78]) (**Table [3](#T3){ref-type="table"}**). No data are yet available for the other opioid peptide KO mice concerning cannabinoid physical dependence. Collectively, available data indicate the involvement of the enkephalinergic system, with a cooperative action of mu and delta receptors, in the expression of cannabinoid dependence.

OPIOID REINFORCING EFFECTS IN CANNABINOID KNOCKOUT MICE
=======================================================

Knockout approaches have greatly improved our knowledge on the role of CB1 receptors in addiction in general, even though contradictory data exist ([@B94]). In particular, for opiate responses (**Table [3](#T3){ref-type="table"}**) induced by mu agonists, CB1 KO mice showed no morphine-induced place preference (5 mg/kg, s.c., 3 injections over 6 days) ([@B101]) and a diminished propensity to self-administer morphine ([@B75]; [@B20]). A microdialysis study revealed that morphine-induced increase of extracellular DA was not observed in CB1 KO mice ([@B102]). Taken together, these data suggest a reduction in morphine's reinforcing activity in the absence of the CB1 receptor. Another study could not reveal any changes in place preference using a slightly more intensive conditioning paradigm and a different set up with two doses of morphine (4 or 8 mg/kg, four injections over 4 days) ([@B136]). Interestingly, no differences between WT and CB1 KO mice could be observed in a CPA paradigm where the opioid antagonist naloxone was used to induce withdrawal in morphine-treated mice via two distinct paradigms ([@B101]; [@B136]). Upon chronic morphine treatment, naloxone-induced withdrawal signs measured in WT animals were attenuated ([@B75]; [@B78]). Together, these findings suggest that CB1 receptors are not involved in the disphoric effects of morphine withdrawal (CPA) but are noticeably required for the development of physical dependence or of somatic signs of opiate withdrawal. Surprisingly, other important effects of morphine, like acute induced analgesia and tolerance to chronic morphine-induced analgesia, were not altered in CB1 KO animals. These findings together with the data on mu opioid KO mice with cannabinoid treatments suggest a bidirectional influence of mu opioid and CB1 cannabinoid receptors on reward processes. Aversive effects of the kappa opioid agonist U50,488H were also blunted in CB1 receptor KO mice ([@B75]). Together with the data of kappa opioid and Pdyn KO mice, it indicates that both cannabinoid and opioid systems modulate negative motivational drug effects. To our knowledge, no data concerning the specific effect of delta selective opioid agonists on reward in CB1 KO mice are available. Interestingly, it has been demonstrated that the absence of CB1 receptor also results in a reduction of the sensitivity to the rewarding properties of sucrose ([@B143]), as well as other reinforcers (for recent reviews, see ([@B82]; [@B93]). Together with pharmacological approaches ([@B94]), KO data therefore provide confirmatory support that CB1 receptor play a modulatory role in the reinforced behaviors maintained by sucrose and some other reinforcers with, in particular, a mutual interaction of opioid and cannabinoid systems.

For the other components of the endocannabinoid system, no specific data for genetically modified animals were reported for the investigation of opioid reward, although pharmacological inhibition of the endocannabinoid catabolic enzymes attenuates both naloxone-induced withdrawal as well as spontaneous withdrawal signs in morphine dependent mice ([@B135], [@B134]), indicating a potential role of these enzymes in opioid dependence.

CONCLUSION AND PERSPECTIVES
===========================

Globally, despite some compensatory alterations at both opioid and cannabinoid levels in mutant lines, KO studies have provided insights into the mutual role of both opioid and cannabinoid systems on reward. In particular, these studies have highlighted the major role for both mu opioid and CB1 receptors in these processes. Clearly, the mu opioid receptor is a convergent molecular target mediating rewarding properties of opioid compounds but also of other drugs of abuse, including cannabinoids. CB1 receptor also appears as a modulator of opioid reward. On the other hand, KO approaches for endogenous opioid peptides or enzymes for synthesis or degradation of endocannabinoids have been very useful to clarify their specific role in both endogenous systems but less/no data are available for reward mechanisms. These mutants therefore need further investigations to clarify their potential implication in cannabinoid/opioid reward aspects.

Conventional genetically modified animals have strengthened our current knowledge of the interaction between these two systems, but further studies using conditional approaches will be necessary to clarify the potential crosstalk existing specifically in reward processes. Interaction between these two neuromodulator systems may be dependent on the brain area where it occurs, even inside the brain rewarding networks ([@B125]). Both mu opioid and CB1 receptors are highly expressed in these networks in similar brain structures and a potential interaction in areas where they are both strongly expressed is probable. Noticeably, opposite expression levels are observed in discrete areas like amygdala (BLA versus central amygdala) as well as habenula (medial versus lateral nuclei) and these differences may also account for a modulatory role of the two systems in reward processes (**Figure [1](#F1){ref-type="fig"}**). Approaches using double mutants for both receptors would be useful to further understand their mutual role in drug reward. Moreover, in this perspective, conditional approaches will surely provide invaluable insights into opioid and cannabinoid interaction at the circuitry level. The growing number of cKO mutant lines becoming available will help this side of research. Likewise, the implication of the CB2 receptor in these interactions has not yet been explored and may be particularly relevant in specific brain structures. In fact, demonstration of CB2 expression in several brain structures has opened a field of investigation for a possible role in addiction that should help to reveal potential direct interaction between CB2 and the opioid system.

G protein coupled receptor can associate as heteromers and extended research is now directed toward elucidating the physiological role of such heteromers and finding therapeutical approaches targeting these entities (see recent reviews [@B47]; [@B103]). Several lines of evidence have suggested interactions between delta or mu opioid receptors and the CB1 receptors. Close vicinity of CB1 receptors with mu or delta opioid receptors has recently been established at the neuronal level, suggesting heteromeric formation *in vivo* and potential impact on both receptors signaling properties. A recent study demonstrated an important role for the heterodimer CB1-delta in neuropathic pain where cortical functions of delta receptor were altered ([@B12]). CB1 and mu receptors associate as heteromers in cultured cells and a recent study showed that bivalent ligands for both receptors are potent analgesic devoid of tolerance ([@B74]), suggesting potential functional heteromers in pain. Therefore, one can easily predict that similar mechanisms may occur in another pathological state like addiction and this opens up new prospects for pharmacological action of cannabinoid and opioid drugs. In this context, it will be critical to see whether CB2 also plays a role as a potential heteromeric interactor with opioid receptors.

No effective therapeutic approaches for cannabis dependence are currently available and opioid addiction therapies are not fully satisfying for all patients. Further studies are therefore needed to clarify the mechanistic basis of interaction of the two systems, which would aid in the development of drug therapies to reduce dependence and abuse. Antibodies or bivalent ligands as mentioned previously represent interesting therapeutic targets. In addition, dual enkephalinase inhibitors and cannabinoid catabolic enzyme inhibitors have been proposed as attractive therapeutic targets to treat pain ([@B140]) and such bi-functional compounds may also be relevant as promising strategies for alleviating dependence.

Substantial progress has been made in understanding the cellular and molecular mechanisms of prolonged use of cannabinoid or opioid drugs ([@B72]; [@B45]). In addition to their direct role in reward, interaction between opioid and cannabinoid neuromodulator systems has been proposed to explain some aspects of vulnerability to addiction and, in this perspective, recent attention has been focused on yet another critical level, epigenetics. These molecular processes, including methylation of DNA, post-translational modifications of histones and regulation by microRNA, regulate gene expression and are crucial in long-term adaptations induced by drugs ([@B114]). Recent studies have shown a direct association between THC-induced Penk upregulation through reduction of histone H3 lysine 9 pattern of methylation and increased heroin SA ([@B167]). Adolescent THC-exposure also resulted in altered heroin SA in the subsequent generation of rats, an effect associated with changes in mRNA expression of cannabinoid, DA, and glutamatergic receptor genes in the striatum, suggesting adaptations to long-term drug effect and germline transmission, most likely involving epigenetic changes ([@B162]). How these neuromodulator systems are dependent on various internal and external environmental factors, and therefore are involved in epigenetics and whether one system influences the epigenetic machinery to control the other system, are unresolved questions for upcoming studies ([@B25]). Future investigation in this field will be necessary to better delineate the neurobiological mechanisms underlying these neuroadaptations.
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